Zdrowie i gospodarka · 07/11/2017

FDA Exempts Autosomal Recessive Carrier Screening Gene Mutation Detection Systems from Premarket Notification Requirements

The FDA is publishing an order to exempt autosomal recessive carrier screening gene mutation detection systems from the premarket notification requirements, effective immediately, to reduce regulatory burdens on the medical device industry and eliminate compliance costs.